查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1886904

肿瘤正子断层扫描（PET）市场规模、占有率、成长及全球产业分析：按类型、应用和地区划分的洞察，以及2024-2032年预测

Oncology Positron Emission Tomography Scan Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 165 Pages | 商品交期: 请询问到货日

价格

肿瘤PET市场成长驱动因子

由于癌症发生率上升和对精准诊断影像的需求不断增长，全球肿瘤PET市场持续扩张。 2024年市场规模为117.4亿美元，预计2025年将达到123.1亿美元。预计2032年将进一步成长至180.4亿美元，预测期内复合年增长率（CAGR）为5.6%。 2024年，北美地区占52.55%的市场占有率，这主要得益于技术应用的普及、广泛的影像基础设施以及较高的癌症筛检率。

PET扫描在肿瘤学中发挥重要作用，包括癌症分期、治疗计划制定和疗效评估。这种使用放射性追踪剂的非侵入性影像技术能够检测细胞层面的代谢活动，因此对癌症早期检测至关重要。全球癌症发生率的不断上升、PET基础设施的投资以及先进PET/CT系统的出现，正在加速PET在全球的应用。

市场动态

市场驱动因素

市场扩张的主要驱动因素是全球癌症负担的日益加重，这推动了国家筛检计画的实施和先进影像系统的快速普及。由于PET扫描具有较高的诊断准确性和在个人化癌症治疗中的价值，世界各地的医疗机构都在采用这项技术。更新的临床指南，例如核子医学与分子影像学会（SNMMI）和美国国家综合癌症网络（NCCN）在2022年推荐使用新型PET显影剂PYLARIFY治疗前列腺癌，也推动了PET扫描的普及。

对早期诊断、精准肿瘤学和治疗监测的日益重视持续推动着对PET影像的需求。根据美国癌症协会预测，到2025年，美国将新增超过313,780例前列腺癌病例，凸显了对更先进诊断技术的迫切需求。

市场限制因子

PET系统的高昂成本仍然是一个主要挑战，限制了其在发展中国家的普及。入门级扫描仪的价格约为475,000美元，而高端型号的价格超过750,000美元，这使得小型医院的安装和维护成为一项沉重的经济负担。此外，放射性示踪剂的製备、人员专业技能和基础建设也推高了营运成本。

有限的保险报销进一步阻碍了PET的普及。在许多发展中国家，PET扫描的资金不足或仅部分报销，这成为诊断普及的障碍。即使在已开发地区，保险也可能不涵盖多次扫描或某些类型的癌症，从而限制了市场供应。

市场机会

将人工智慧 (AI) 整合到肿瘤学的 PET 成像中蕴藏着巨大的机会。 AI 工具可增强病灶侦测、自动进行肿瘤定量分析并提高工作流程效率。例如，西门子医疗于 2023 年推出了 Biograph Vision PET/CT，其采用先进的飞行时间成像 (TOF) 技术，可显着提高诊断清晰度。随着 AI 系统获得监管部门的批准，预计其应用将加速全球 PET 成像效率的提升。

市场挑战

放射性示踪剂供应链持续存在的瓶颈构成了一项重大挑战。 FDG 等放射性示踪剂的半衰期很短，因此需要高效率的物流。任何延误都会促使检测计划被打乱，等待时间延长。在英国，2024 年的数据显示，92% 的癌症患者至少需要等待 31 天才能接受筛检，部分原因是放射性追踪剂供应瓶颈。此外，全球对有限的同位素供应商的依赖使得医疗保健系统在生产中断时非常脆弱。

市场趋势

一个值得注意的趋势是向 "诊疗一体化" 的转变，它将诊断性 PET 影像与标靶放射性核素治疗相结合。基于 PSMA 的 PET 影像用于前列腺癌，以及用于神经内分泌肿瘤的新型示踪剂，都显示人们对精准肿瘤学的兴趣日益浓厚。影像生物标记的进步也正在改变治疗计划，使其能够预测和即时监测治疗结果。

细分市场概览

按付款方式

2024 年，私人保险/自费市场占主导地位，这主要得益于患者对更快、更高品质的肿瘤诊断的需求。癌症治疗费用不断上涨也推动了私人支出的增加。由于全球致力于将PET影像技术纳入政府资助的癌症项目，公共医疗市场也实现了成长。

依服务提供者划分

2024年，医院凭藉先进的成像基础设施和训练有素的放射科团队，占了市场主导地位。然而，由于成本效益高、等待时间短以及PET/CT投资不断增加，预计诊断中心将成长最快。

依地区划分

北美（2024年为61.7亿美元）

该地区凭藉其强大的医疗基础设施和先进的PET系统高普及率，在全球市场中处于领先地位。下一代扫描仪的引入，例如亚利桑那州的Omni Legend 32 PET/CT（2024年），标誌着医疗技术的持续现代化。

欧洲

市场成长主要受癌症病例增加及PET造影剂应用范围扩大的推动。 2025年，Telix Pharmaceuticals的Illuccix在瑞典获批，用于辅助晚期摄护腺癌的影像诊断。

亚太地区

由于医疗保健系统的扩张、筛检计画的增加以及示踪剂商业化合作的增加（例如Curium与日本PeptiDream的合作），预计亚太市场将实现最高的复合年增长率。

拉丁美洲、中东和非洲

由于癌症发生率上升以及PET-CT系统安装量的增加（包括巴西和沙乌地阿拉伯的新中心），这些地区具有强劲的成长潜力。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：主要发现

  • 主要国家癌症盛行率
  • 主要公司新产品发布
  • 主要产业趋势（併购、合作等）
  • 肿瘤PET技术进展

第五章：全球肿瘤正子断层扫描市场分析、洞察与预测 2019-2032

  • 市场分析、洞察与预测 - 按支付方式划分
    • 公共支付
    • 私人医疗保险/自费
  • 市场分析、洞察与预测 - 按服务提供者划分
    • 医院
    • 诊断中心
    • 其他
  • 市场分析、洞察与预测 - 按地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章 北美肿瘤正子断层扫描市场分析、洞察与预测 (2019-2032)

  • 依国家划分
    • 美国州/省
    • 加拿大

第七章：欧洲肿瘤正子断层扫描市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 义大利
    • 斯堪的纳维亚半岛
    • 欧洲其他地区

第八章：亚太地区肿瘤正子断层扫描市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 东南亚
    • 其他地区亚太地区

第九章：拉丁美洲肿瘤正子断层扫描市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区

第十章：中东与非洲肿瘤正子断层扫描市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 海湾合作委员会
    • 南非
    • 中东和非洲其他地区

第十一章 竞争分析

  • 全球市占率分析（2024）
  • 公司简介
  • GE医疗
  • Sonic Healthcare Limited
  • Oncovision
  • 皇家飞利浦
  • Apex Radiology
  • Alliance Medical Limited
  • Novant Health
  • 佳能医疗系统
  • Dignity Health
  • Concord Medical
  • 西门子医疗股份有限公司
  • Mediworks
  • 其他主要参与者
Product Code: FBI113540

Growth Factors of oncology positron emission tomography (PET) scan Market

The global oncology positron emission tomography (PET) scan market continues to expand as cancer incidence rises and demand for accurate diagnostic imaging intensifies. The market was valued at USD 11.74 billion in 2024, is expected to reach USD 12.31 billion in 2025, and is projected to rise to USD 18.04 billion by 2032, reflecting a CAGR of 5.6% during the forecast period. North America accounted for 52.55% of the market share in 2024, supported by strong technological adoption, extensive imaging infrastructure, and high cancer screening rates.

Oncology PET scans serve as critical tools for staging cancer, guiding treatment decisions, and evaluating therapeutic response. This non-invasive imaging technique, driven by radiotracers, allows clinicians to detect metabolic activity at a cellular level, making it indispensable for early cancer detection. The increasing prevalence of cancer worldwide, investment in PET infrastructure, and emergence of advanced PET/CT systems are accelerating global adoption.

Market Dynamics

Market Drivers

A major driver of market expansion is the rising global cancer burden, leading to the implementation of national screening programs and rapid deployment of advanced imaging systems. Healthcare organizations globally are adopting PET scans due to their high diagnostic accuracy and value in personalized cancer treatment. Updated clinical guidelines, such as the 2022 SNMMI and NCCN endorsement of novel PET agents like PYLARIFY for prostate cancer, further support adoption.

Growing emphasis on early diagnosis, precision oncology, and therapy monitoring continues to push demand for PET imaging. As per the American Cancer Society, over 313,780 new cases of prostate cancer are expected in the U.S. in 2025, underscoring the need for enhanced diagnostic modalities.

Market Restraints

A major challenge remains the high cost of PET systems, which restricts penetration in developing markets. Entry-level scanners cost approximately USD 475,000, while high-end scanners exceed USD 750,000, making installation and maintenance financially burdensome for smaller hospitals. Additionally, radiotracer preparation, staff expertise, and infrastructure add to operational costs.

Reimbursement limitations further hinder accessibility. In several developing economies, PET scans remain underfunded or partially covered, creating barriers to diagnostic adoption. Even in developed regions, insurance may not support multiple scans or certain cancer types, limiting market utilization.

Market Opportunities

Integration of artificial intelligence (AI) in oncology PET imaging presents significant opportunities. AI tools enhance lesion detection, automate tumor quantification, and improve workflow efficiency. For instance, Siemens Healthineers' Biograph Vision PET/CT, launched in 2023, features advanced time-of-flight imaging that improves diagnostic clarity. As AI-enabled systems gain regulatory approvals, their adoption is poised to accelerate PET imaging efficiency globally.

Market Challenges

Persistent radiotracer supply chain constraints represent a crucial challenge. Radiotracers such as FDG have short half-lives, demanding efficient logistics. Any delay disrupts scheduling and increases waiting times. In the U.K., 2024 data showed 92% of cancer patients waited at least 31 days for screenings, partly due to radiotracer bottlenecks. Global dependence on limited isotope suppliers also makes health systems vulnerable to production disruptions.

Market Trends

A defining trend is the shift toward theranostics, which combines diagnostic PET imaging with targeted radionuclide therapy. PSMA-based PET imaging for prostate cancer and novel tracers for neuroendocrine tumors illustrate the growing interest in precision oncology. Advancements in imaging biomarkers are also transforming treatment planning by enabling prediction of therapy outcomes and real-time monitoring.

Segmentation Overview

By Source of Payment

The private insurance/out-of-pocket segment dominated 2024, driven by patient preference for faster access to premium oncology diagnostics. Rising cancer treatment costs reinforce the shift toward private spending. The public segment also grew due to global efforts to integrate PET imaging into government-funded cancer programs.

By Service Provider

Hospitals dominated the market in 2024, backed by advanced imaging infrastructure and trained radiology teams. Diagnostic centers, however, are projected to grow fastest due to cost-effectiveness, shorter wait times, and rising investments in PET/CT acquisition.

Regional Overview

North America (USD 6.17 billion in 2024)

The region leads globally due to strong healthcare infrastructure and high adoption of advanced PET systems. Installations of new-generation scanners-such as Omni Legend 32 PET/CT in Arizona (2024)-highlight ongoing modernization.

Europe

Market growth is driven by rising cancer cases and expansion of PET imaging agents. In 2025, Telix Pharmaceuticals' Illuccix received Swedish approval, supporting advanced prostate cancer imaging.

Asia Pacific

Expected to record the highest CAGR, driven by expanding healthcare systems, growing screening programs, and rising tracer commercialization partnerships, such as Curium and PeptiDream's collaboration in Japan.

Latin America & Middle East-Africa

These regions show strong growth potential due to increasing cancer prevalence and expanding installation of PET CT systems, including new centers in Brazil and Saudi Arabia.

Conclusion

Driven by rising cancer cases, AI integration, and advancements in theranostics, the oncology PET scan market is projected to increase from USD 11.74 billion in 2024 to USD 18.04 billion by 2032. Continuous investments in next-generation PET technologies will continue shaping the global cancer diagnostics landscape.

Segmentation By Source of Payment

  • Public
  • Private Health Insurance/Out-of-pocket

By Service Providers

  • Hospitals
  • Diagnostic Centers
  • Others

By Region

  • North America (By Source of Payment, Service Providers, and Country)
    • U.S.
    • Canada
  • Europe (By Source of Payment, Service Providers, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Source of Payment, Service Providers, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Source of Payment, Service Providers, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Source of Payment, Service Providers, and Country/Sub-region)
    • GCC
    • South Africa
  • Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Cancer, Key Countries
  • 4.2. New Product Launches, By Key Players
  • 4.3. Key Industry Developments (Mergers, Acquisitions, Partnerships, and Others)
  • 4.4. Technological Advancements in Oncology PET

5. Global Oncology Positron Emission Tomography Scan Market Analysis, Insights and Forecast, 2019-2032

  • 5.1. Market Analysis, Insights and Forecast - By Source of Payment
    • 5.1.1. Public
    • 5.1.2. Private Health Insurance/Out-of-pocket
  • 5.2. Market Analysis, Insights and Forecast - By Service Providers
    • 5.2.1. Hospitals
    • 5.2.2. Diagnostic Centers
    • 5.2.3. Others
  • 5.3. Market Analysis, Insights and Forecast - By Region
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. Asia Pacific
    • 5.3.4. Latin America
    • 5.3.5. Middle East & Africa

6. North America Oncology Positron Emission Tomography Scan Market Analysis, Insights and Forecast, 2019-2032

  • 6.1. Market Analysis, Insights and Forecast - By Source of Payment
    • 6.1.1. Public
    • 6.1.2. Private Health Insurance/Out-of-pocket
  • 6.2. Market Analysis, Insights and Forecast - By Service Providers
    • 6.2.1. Hospitals
    • 6.2.2. Diagnostic Centers
    • 6.2.3. Others
  • 6.3. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 6.3.1. U.S.
    • 6.3.2. Canada

7. Europe Oncology Positron Emission Tomography Scan Market Analysis, Insights and Forecast, 2019-2032

  • 7.1. Market Analysis, Insights and Forecast - By Source of Payment
    • 7.1.1. Public
    • 7.1.2. Private Health Insurance/Out-of-pocket
  • 7.2. Market Analysis, Insights and Forecast - By Service Providers
    • 7.2.1. Hospitals
    • 7.2.2. Diagnostic Centers
    • 7.2.3. Others
  • 7.3. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.3.1. U.K.
    • 7.3.2. Germany
    • 7.3.3. France
    • 7.3.4. Spain
    • 7.3.5. Italy
    • 7.3.6. Scandinavia
    • 7.3.7. Rest of Europe

8. Asia Pacific Oncology Positron Emission Tomography Scan Market Analysis, Insights and Forecast, 2019-2032

  • 8.1. Market Analysis, Insights and Forecast - By Source of Payment
    • 8.1.1. Public
    • 8.1.2. Private Health Insurance/Out-of-pocket
  • 8.2. Market Analysis, Insights and Forecast - By Service Providers
    • 8.2.1. Hospitals
    • 8.2.2. Diagnostic Centers
    • 8.2.3. Others
  • 8.3. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.3.1. Japan
    • 8.3.2. China
    • 8.3.3. India
    • 8.3.4. Australia
    • 8.3.5. Southeast Asia
    • 8.3.6. Rest of Asia Pacific

9. Latin America Oncology Positron Emission Tomography Scan Market Analysis, Insights and Forecast, 2019-2032

  • 9.1. Market Analysis, Insights and Forecast - By Source of Payment
    • 9.1.1. Public
    • 9.1.2. Private Health Insurance/Out-of-pocket
  • 9.2. Market Analysis, Insights and Forecast - By Service Providers
    • 9.2.1. Hospitals
    • 9.2.2. Diagnostic Centers
    • 9.2.3. Others
  • 9.3. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.3.1. Brazil
    • 9.3.2. Mexico
    • 9.3.3. Rest of Latin America

10. Middle East & Africa Oncology Positron Emission Tomography Scan Market Analysis, Insights and Forecast, 2019-2032

  • 10.1. Market Analysis, Insights and Forecast - By Source of Payment
    • 10.1.1. Public
    • 10.1.2. Private Health Insurance/Out-of-pocket
  • 10.2. Market Analysis, Insights and Forecast - By Service Providers
    • 10.2.1. Hospitals
    • 10.2.2. Diagnostic Centers
    • 10.2.3. Others
  • 10.3. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 10.3.1. GCC
    • 10.3.2. South Africa
    • 10.3.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2024)
  • 11.2. Company Profiles (Overview, Products, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
    • 11.2.1. GE Healthcare
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Sonic Healthcare Limited
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Oncovision
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Koninklijke Philips N.V.
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Apex Radiology
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Alliance Medical Limited
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Novant Health
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Canon Medical Systems
      • 11.2.8.1. Overview
      • 11.2.8.2. Products
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Dignity Health
      • 11.2.9.1. Overview
      • 11.2.9.2. Products
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)
    • 11.2.10. Concord Medical
      • 11.2.10.1. Overview
      • 11.2.10.2. Products
      • 11.2.10.3. SWOT Analysis
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. Financials (Based on Availability)
    • 11.2.11. Siemens Healthcare Limited
      • 11.2.11.1. Overview
      • 11.2.11.2. Products
      • 11.2.11.3. SWOT Analysis
      • 11.2.11.4. Recent Developments
      • 11.2.11.5. Strategies
      • 11.2.11.6. Financials (Based on Availability)
    • 11.2.12. Mediworks
      • 11.2.12.1. Overview
      • 11.2.12.2. Products
      • 11.2.12.3. SWOT Analysis
      • 11.2.12.4. Recent Developments
      • 11.2.12.5. Strategies
      • 11.2.12.6. Financials (Based on Availability)
    • 11.2.13. Other Prominent Players
      • 11.2.13.1. Overview
      • 11.2.13.2. Products
      • 11.2.13.3. SWOT Analysis
      • 11.2.13.4. Recent Developments
      • 11.2.13.5. Strategies
      • 11.2.13.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, by Source of Payment, 2019-2032
  • Table 2: Global Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, by Service Providers, 2019-2032
  • Table 3: Global Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, by Region, 2019-2032
  • Table 4: North America Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, by Source of Payment, 2019-2032
  • Table 5: North America Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, by Service Providers, 2019-2032
  • Table 6: North America Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, By Country, 2019-2032
  • Table 7: Europe Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, by Source of Payment, 2019-2032
  • Table 8: Europe Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, by Service Providers, 2019-2032
  • Table 9: Europe Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 10: Asia Pacific Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, by Source of Payment, 2019-2032
  • Table 11: Asia Pacific Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, by Service Providers, 2019-2032
  • Table 12: Asia Pacific Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 13: Latin America Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, by Source of Payment, 2019-2032
  • Table 14: Latin America Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, by Service Providers, 2019-2032
  • Table 15: Latin America Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 16: Middle East & Africa Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, by Source of Payment, 2019-2032
  • Table 17: Middle East & Africa Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, by Service Providers, 2019-2032
  • Table 18: Middle East & Africa Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032

List of Figures

  • Figure 1: Global Oncology Positron Emission Tomography Scan Market Revenue Breakdown (USD billion, %) by Region, 2024 & 2032
  • Figure 2: Global Oncology Positron Emission Tomography Scan Market Value Share (%), by Source of Payment, 2024 & 2032
  • Figure 3: Global Oncology Positron Emission Tomography Scan Market Value Share (%), by Service Providers, 2024 & 2032
  • Figure 4: Global Oncology Positron Emission Tomography Scan Market Value Share (%), by Region, 2024 & 2032
  • Figure 5: North America Oncology Positron Emission Tomography Scan Market Value (USD billion), by Source of Payment, 2024 & 2032
  • Figure 6: North America Oncology Positron Emission Tomography Scan Market Value Share (%), by Source of Payment, 2024
  • Figure 7: North America Oncology Positron Emission Tomography Scan Market Value (USD billion), by Service Providers, 2024 & 2032
  • Figure 8: North America Oncology Positron Emission Tomography Scan Market Value Share (%), by Service Providers, 2024
  • Figure 9: North America Oncology Positron Emission Tomography Scan Market Value (USD billion), By Country, 2024 & 2032
  • Figure 10: North America Oncology Positron Emission Tomography Scan Market Value Share (%), By Country, 2024
  • Figure 11: Europe Oncology Positron Emission Tomography Scan Market Value (USD billion), by Source of Payment, 2024 & 2032
  • Figure 12: Europe Oncology Positron Emission Tomography Scan Market Value Share (%), by Source of Payment, 2024
  • Figure 13: Europe Oncology Positron Emission Tomography Scan Market Value (USD billion), by Service Providers, 2024 & 2032
  • Figure 14: Europe Oncology Positron Emission Tomography Scan Market Value Share (%), by Service Providers, 2024
  • Figure 15: Europe Oncology Positron Emission Tomography Scan Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 16: Europe Oncology Positron Emission Tomography Scan Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 17: Asia Pacific Oncology Positron Emission Tomography Scan Market Value (USD billion), by Source of Payment, 2024 & 2032
  • Figure 18: Asia Pacific Oncology Positron Emission Tomography Scan Market Value Share (%), by Source of Payment, 2024
  • Figure 19: Asia Pacific Oncology Positron Emission Tomography Scan Market Value (USD billion), by Service Providers, 2024 & 2032
  • Figure 20: Asia Pacific Oncology Positron Emission Tomography Scan Market Value Share (%), by Service Providers, 2024
  • Figure 21: Asia Pacific Oncology Positron Emission Tomography Scan Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 22: Asia Pacific Oncology Positron Emission Tomography Scan Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 23: Latin America Oncology Positron Emission Tomography Scan Market Value (USD billion), by Source of Payment, 2024 & 2032
  • Figure 24: Latin America Oncology Positron Emission Tomography Scan Market Value Share (%), by Source of Payment, 2024
  • Figure 25: Latin America Oncology Positron Emission Tomography Scan Market Value (USD billion), by Service Providers, 2024 & 2032
  • Figure 26: Latin America Oncology Positron Emission Tomography Scan Market Value Share (%), by Service Providers, 2024
  • Figure 27: Latin America Oncology Positron Emission Tomography Scan Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 28: Latin America Oncology Positron Emission Tomography Scan Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 29: Middle East & Africa Oncology Positron Emission Tomography Scan Market Value (USD billion), by Source of Payment, 2024 & 2032
  • Figure 30: Middle East & Africa Oncology Positron Emission Tomography Scan Market Value Share (%), by Source of Payment, 2024
  • Figure 31: Middle East & Africa Oncology Positron Emission Tomography Scan Market Value (USD billion), by Service Providers, 2024 & 2032
  • Figure 32: Middle East & Africa Oncology Positron Emission Tomography Scan Market Value Share (%), by Service Providers, 2024
  • Figure 33: Middle East & Africa Oncology Positron Emission Tomography Scan Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 34: Middle East & Africa Oncology Positron Emission Tomography Scan Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 35: Global Oncology Positron Emission Tomography Scan Market Share (%), By Company, 2024